RxDoctor Payments Data

Maciej Malinski, MD

Interventional Cardiology · Elgin, ILNPI 1609847623

Payments from drug & device makers

$26,745in general payments, 2019–2025

Across 706 payments — averaging $37.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$3K
  • Avinger Inc.$3K
  • Boston Scientific$2K
  • Medtronic$2K
  • Abbott$2K
  • Edwards Lifesciences$2K
  • plus $12K from 38 others

What the payments were for

  • Travel & lodging$6,34024%
  • Food & beverage$20,40676%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,745 in reported general payments places this provider in the 70th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$259,598
Medicare patients
939
Services billed
2,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban194$229,370
EliquisApixaban156$177,693
EntrestoSacubitril/Valsartan106$146,049
Repatha SureclickEvolocumab76$60,622
JardianceEmpagliflozin28$40,955
Praluent PenAlirocumab51$40,027
Metoprolol Succinate556$9,964
Rosuvastatin Calcium579$8,055
Ezetimibe155$4,679
Atorvastatin Calcium324$4,233
Losartan Potassium393$3,816
ClopidogrelClopidogrel Bisulfate201$3,006
Nifedipine ErNifedipine50$2,349
Bumetanide71$2,203
Spironolactone170$1,303

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$3,439$229,370194 claims
PfizerEliquis$24$177,693156 claims
NovartisEntresto$396$146,049106 claims
Boehringer IngelheimJardiance$709$40,95528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →